Bavarian Nordic (CPSE:BAVA) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BAVA 주식 개요

바이에른 노르딕 A/S는 생명을 구하는 백신을 개발, 제조 및 상용화하는 기업입니다.

BAVA 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	1/6
과거 실적	1/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 55.2% 에서 거래

수익은 매년 35.58% 증가할 것으로 예상됩니다.

위험 분석

이익 마진 (11.6%) 작년보다 낮습니다 (19.5%)

최근 3개월간 주가 변동성

재무 결과에 영향을 미치는 대규모 일회성 항목

지난 3개월간 상당한 내부자 매도

Bavarian Nordic A/S 경쟁사

Genmab

CPSE:GMAB

DKK 103.0b

ALK-Abelló

CPSE:ALK B

DKK 38.0b

PeptiDream

TSE:4587

JP¥352.5b

H. Lundbeck

CPSE:HLUN B

DKK 42.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Bavarian Nordic
과거 주가
현재 주가	DKK 234.40
52주 최고치	DKK 300.00
52주 최저치	DKK 125.55
베타	1.54
11개월 변경	-11.88%
3개월 변경 사항	36.56%
1년 변경 사항	47.89%
33년 변화	-24.39%
5년 변화	32.13%
IPO 이후 변화	-8.08%

최근 뉴스 및 업데이트

Recent updates

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

주주 수익률

	BAVA	DK Biotechs	DK 마켓
7D	-3.1%	-6.1%	-3.7%
1Y	47.9%	-7.2%	19.0%

수익률 대 산업: BAVA 지난 1년 동안 2.1 %를 반환한 Danish Biotechs 산업을 초과했습니다.

수익률 대 시장: BAVA 지난 1년 동안 22.8 %를 반환한 Danish 시장을 초과했습니다.

가격 변동성

Is BAVA's price volatile compared to industry and market?
BAVA volatility
BAVA Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.0%
10% least volatile stocks in DK Market	2.4%

안정적인 주가: BAVA 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BAVA 의 주간 변동성( 10% )은 지난 1년 동안 안정적이었지만 여전히 Danish 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

바이에른 노르딕 A/S는 생명을 구하는 백신을 개발, 제조 및 상업화합니다. 이 회사는 비복제 천연두 및 수두 백신을 IMVAMUNE, IMVANEX, JYNNEOS라는 이름으로, 인체용 광견병 백신은 Rabipur/RabAvert라는 이름으로, 진드기 매개 뇌염 백신은 Encepur라는 이름으로, 에볼라 백신은 MVABEA라는 이름으로 공급하고 있습니다. 또한 천연두 치료를 위한 MVA-BN, 호흡기 세포융합 바이러스 치료를 위한 임상 3상 시험 중인 MVA-BN RSV, SARS-CoV-2 치료를 위한 임상 3상 시험을 완료한 ABNCoV2를 개발 중입니다.

Bavarian Nordic A/S 기본 사항 요약

Bavarian Nordic 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BAVA 기본 통계
시가총액	DKK 18.41b
수익(TTM)	DKK 707.42m
수익(TTM)	DKK 6.08b

26.0x

P/E 비율

3.0x

P/S 비율

BAVA 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BAVA 손익 계산서(TTM)
수익	DKK 6.08b
수익 비용	DKK 2.06b
총 이익	DKK 4.02b
기타 비용	DKK 3.31b
수익	DKK 707.42m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

Nov 15, 2024

주당 순이익(EPS)	9.01
총 마진	66.08%
순이익 마진	11.63%
부채/자본 비율	0.2%

BAVA 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BAVA 주식 개요

보상

위험 분석

Bavarian Nordic A/S 경쟁사

CPSE:GMAB

DKK 103.0b

CPSE:ALK B

DKK 38.0b

TSE:4587

JP¥352.5b

CPSE:HLUN B

DKK 42.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Recent updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.